C12N 2760/10111
Deltavirus
Official title: Deltavirus, e.g. hepatitis delta virus
C12N2760/10111 (Deltavirus) appears on 58 US grants and 42 published applications in this corpus.
Search patents in C12N- Granted patents
- 58
- Published applications
- 42
- Assignees
- 34
- Inventors
- 92
- Latest grant
- 12 Dec 2023
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1993 | 2 | 0 |
| 1994 | 0 | 0 |
| 1995 | 4 | 0 |
| 1996 | 1 | 0 |
| 1997 | 3 | 0 |
| 1998 | 8 | 0 |
| 1999 | 5 | 0 |
| 2000 | 2 | 0 |
| 2001 | 3 | 0 |
| 2002 | 4 | 2 |
| 2003 | 5 | 4 |
| 2004 | 0 | 2 |
| 2005 | 1 | 2 |
| 2006 | 2 | 1 |
| 2007 | 0 | 1 |
| 2008 | 1 | 1 |
| 2009 | 0 | 0 |
| 2010 | 0 | 1 |
| 2011 | 1 | 2 |
| 2012 | 1 | 1 |
| 2013 | 0 | 0 |
| 2014 | 2 | 3 |
| 2015 | 0 | 1 |
| 2016 | 2 | 2 |
| 2017 | 2 | 2 |
| 2018 | 2 | 3 |
| 2019 | 0 | 1 |
| 2020 | 2 | 1 |
| 2021 | 3 | 5 |
| 2022 | 1 | 1 |
| 2023 | 1 | 1 |
| 2024 | 0 | 2 |
| 2025 | 0 | 2 |
| 2026 | 0 | 1 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
- C12N 2760/10122New viral proteins or individual genes, new structural or functional aspects ofIndexing code49
- C12N 2760/10134Use of virus or viral component as vaccineIndexing code7
- C12N 2760/10161Methods of inactivation or attenuationIndexing code5
- C12N 2760/10121Viruses as suchIndexing code1
- C12N 2760/10133Use of viral protein as therapeutic agent other than vaccineIndexing code1
- C12N 2760/10151Methods of production or purification of viral materialIndexing code1
- C12N 2760/10123Virus like particles [vlp]Indexing code0
- C12N 2760/10131Uses of virus other than therapeutic or vaccineIndexing code0
Recent patents
- Method and means for the rapid detection of HDV infections12 Dec 2023US 11,841,368 B2Universität Heidelberg
- Chimeric hepatitis D virus antigen and hepatitis B virus pre S1 genes for use alone or in vaccines contaning hepatitis B virus genes25 Oct 2022US 11,478,544 B2Svenska Vaccinfabriken Produktion AB
- Viral delivery of RNA utilizing self-cleaving ribozymes and CRISPR-based applications thereof27 Apr 2021US 10,988,779 B2Icahn School of Medicine at Mount Sinai
- Therapy of atherosclerosis, primary biliary cirrhosis and NRLP3 inflammasome-associated disease by HTCP inhibitors23 Feb 2021US 10,925,925 B2Myr GmbH
- Chimeric hepatitis D virus antigen and hepatitis B virus pre S1 genes for use alone or in vaccines containing hepatitis B virus genes2 Feb 2021US 10,905,760 B2Svenska Vaccinfabriken Produktion AB
- Compositions and methods for treating viral infections6 Aug 2026US 2026/0226474 A1The University of Sydney
- Compositions and methods for treating and preventing hepatitis b and d19 Jun 2025US 2025/0197452 A1SVF Vaccines AB
- Methods and systems for diagnosing orthopoxvirus infection8 May 2025US 2025/0147043 A1
- Lassa virus vaccine and uses thereof11 Jul 2024US 2024/0226265 A9Inovio Pharmaceuticals, Inc.
- Lassa virus vaccine and uses thereof25 Apr 2024US 2024/0131143 A1Inovio Pharmaceuticals, Inc.
Most cited
By later US patents
- 2'-O-amino-containing nucleoside analogs and polynucleotides130US 6,159,951 ARibozyme Pharmaceuticals, Inc. · 2000
- Therapeutic ribozyme compositions and expression vectors92US 5,225,347 AInnovir Laboratories, Inc. · 1993
- Assay for Ribozyme target site58US 5,525,468 ARibozyme Pharmaceuticals, Inc. · 1996
- Synthesis deprotection analysis and purification of RNA and ribozymes56US 5,831,071 ARibozyme Pharmaceuticals, Inc. · 1998
- Synthesis, deprotection, analysis and purification of RNA and ribozymes56US 6,469,158 B1Ribozyme Pharmaceuticals, Inc. · 2002